The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1366
Aromatase Inhibitors for Adjuvant Treatment of Postmenopausal Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Adjuvant hormone therapy with anti-estrogen drugs has been shown to reduce disease recurrence and mortality in postmenopausal women with estrogen receptor (ER)-positive breast cancer. In recent years, aromatase inhibitors (AI) have become the preferred first-line hormonal treatment over tamoxifen for such patients.1,2

MECHANISM OF ACTION — Tamoxifen is a selective estrogen receptor modulator that primarily acts as an antagonist at the estrogen receptor. Aromatase inhibitors decrease the agonist effect of estrogen by inhibiting estrogen synthesis.3

CLINICAL TRIALS — A review of 12 prospective, randomized trials in postmenopausal women with hormone receptor-positive breast cancer found that use of an aromatase inhibitor as initial adjuvant therapy, as sequential therapy after 2-3 years of tamoxifen, or as extended ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aromatase Inhibitors for Adjuvant Treatment of Postmenopausal Breast Cancer
Article code: 1366c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian